IP Library Granted Patent US 11,279,917
Granted Patent B2
US 11,279,917 · App. 15/931,310 · Granted Mar 22, 2022

P450-BM3 variants with improved activity

Inventors: Robert Osborne (Raleigh, NC); Vesna Mitchell (Santa Clara, CA); Khin Yu Naing Htwe (Daly City, CA); Xiyun Zhang (Fremont, CA); Erika M. Milczek (New York, NY); Jeffrey C. Moore (Westfield, NJ)
Assignee: Codexis, Inc.
C12N9/0071C07K14/80C12N9/0042C12P13/001C12Y114/14001C12Y106/02004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,279,917
App. No.
15/931,310
Granted
Mar 22, 2022
Kind
B2
Abstract

The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.

Claims (13)

1. A recombinant cytochrome P450-BM3 variant having cytochrome P450-BM3 activity and comprising the amino acid sequence of SEQ ID NO: 48.

2. The recombinant cytochrome P450-BM3 variant of claim 1 , wherein said variant oxidizes at least three organic substrates.

3. The recombinant cytochrome P450-BM3 variant of claim 2 , wherein the at least three organic substrates are selected from the group consisting of nifedipine, propranolol, verapamil, and diclofenac.

4. An isolated polynucleotide comprising a polynucleotide sequence encoding the recombinant cytochrome P450-BM3 variant of claim 1 .

5. The isolated polynucleotide of claim 4 , wherein said polynucleotide comprises the polynucleotide sequence of SEQ ID NO: 47.

6. An expression vector comprising the polynucleotide of claim 4 .

7. The vector of claim 6 , wherein said polynucleotide sequence is operably linked with regulatory sequences suitable for expression of said polynucleotide sequence in a suitable host cell.

8. The vector of claim 7 , wherein said host cell is a prokaryotic or eukaryotic cell.

9. The vector of claim 8 , wherein said host cell is a prokaryotic cell.

10. The vector of claim 8 , wherein said host cell is E. coli.

11. An isolated host cell comprising the vector of claim 6 .

12. A method for producing at least one recombinant cytochrome P450-BM3 variant comprising culturing the host cell of claim 11 under conditions such that the recombinant cytochrome P450-BM3 variant is produced.

13. The method of claim 12 , further comprising the step of recovering said at least one recombinant cytochrome P450-BM3 variant.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (5)
Continuation 16131252 · Sep 14, 2018
Continuation 15619176 · Jun 9, 2017
Division 14794249 · Jul 8, 2015
Provisional Application 62022442 · Jul 9, 2014
Related Publication 20200332268A1 · Oct 22, 2020
Cited By (1)
US 12,365,882